Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034916.xml
Download PDF
Nervenheilkunde 2009; 28(12): 883-888
DOI: 10.1055/s-0038-1628700
DOI: 10.1055/s-0038-1628700
Schwabinger Neuro-Seminar
Schmerzen bei Parkinson-Syndromen
Pain in patients with parkinsonismFurther Information
Publication History
eingegangen am:
21 September 2009
angenommen am:
21 September 2009
Publication Date:
24 January 2018 (online)
Zusammenfassung
Parkinson-Patienten klagen sehr häufig über Schmerzen und Missempfindungen. Dennoch werden Schmerzen bei Parkinson-Patienten häufig unterschätzt, fehldiagnostiziert und -behandelt. Opiate können die ParkinsonSymptomatik verschlechtern und Verwirrtheitszustände hervorrufen. Das therapeutische Vorgehen zielt zunächst auf eine Optimierung der dopaminergen Medikation, da Schmerzen meist mit der Akinese und dem Rigor zusammenhängen und mit motorischen Fluktuationen korrelieren. In einem weiteren Schritt kommt ein multimodaler Therapieansatz mit Analgetika, Physiotherapie und psychoedukativen Maßnahmen zur Anwendung.
Summary
Pain and sensory complaints are common among Parkinson’s disease patients. Despite its high prevalence in Parkinson’s disease the burden of pain is often underestimated, misdiagnosed and not correctly treated. Opiods can exacerbate rigidity and produce confusional states. Therapeutic strategies should firstly aim at a sufficient dopaminergic stimulation since pain is frequently linked to akinesia and rigidity and may fluctuate similarly to motor signs. Secondly, a multimodal approach including analgesics, physiotherapy and psychoeducation is frequently helpful to avoid chronification and impaired quality of life.
-
Literatur
- 1 Boecker H, Ceballos-Baumann AO, Weindl A, Bartenstein P, Siebner H, Faßbender T, Munz F, Schwaiger M, Conrad B. A PET activation study of sensory processing in Parkinson´s disease and Huntington´s disease. Brain 1999; 122: 1651-65.
- 2 Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov Disord 1996; 11 (01) 53-8.
- 3 Brefel-Courbon C, Grolleau S, Thalamas C, Bourrel R, Allaria-Lapierre V, Loi R, Micallef-Roll J, Lapeyre-Mestre M. Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain 2009; 141 (1–2) 14-8.
- 4 Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord 2005; 20 (12) 1557-63.
- 5 Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology 1989; 39 (10) 1309-14.
- 6 Cantello R, Aguggia M, Gilli M, Delsedime M, Riccio A, Rainero I, Mutani R. Analgesic action of methylphenidate on parkinsonian sensory symptoms. Mechanisms and pathophysiological implications. Arch Neurol 1988; 45 (09) 973-6.
- 7 Ceballos-Baumann A, Gündel H. Bewegungsstörungen. In: Henningsen P, Gündel H, CeballosBaumann A. (ed.) Neuropsychosomatik. Stuttgart: Schattauer; 2006
- 8 Ceballos-Baumann AO. Idiopathisches ParkinsonSyndrom: Grundlagen, Medikamente, Therapieeinleitung. In: Ceballos-Baumann AO, Conrad B. (Ed.) Bewegungsstörungen in der Neurologie. 2 Auflage. Stuttgart: Thieme; 2005
- 9 Colosimo C, Salvatori FM. Injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2009; 24 (02) 316-7.
- 10 Decina P, Mukherjee S, Caracci G, Harrison K. Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes. Am J Psychiatry 1992; 149 (08) 1075-80.
- 11 Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol 1993; 33 (05) 490-3.
- 12 Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord. 2009 Jul 30. Epub ahead of print..
- 13 Ford B. Pain in Parkinson’s disease. Clin Neurosci 1998; 05 (02) 63-72.
- 14 Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson’s disease. Mov Disord 1996; 11 (04) 421-6.
- 15 Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson’s disease. Mov Disord 1986; 01 (01) 45-9.
- 16 Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45 (04) 712-7.
- 17 Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson’s disease: a double-blind placebo-controlled study. Neurology 1988; 38 (11) 1720-2.
- 18 Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon?. J Neurol Neurosurg Psychiatry 1988; 51 (12) 1503-7.
- 19 Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord 2009; 24 (08) 1233-7.
- 20 Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O. Chronic pain in Parkinson’s disease: The cross-sectional French DoPaMiP survey. Mov Disord 2008; 23 (10) 1361-9.
- 21 Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995; 10 (03) 333-6.
- 22 Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 1994; 35 (02) 237-9.
- 23 Putzki N, Maschke M, Drepper J, Diener HC, Timmann D. Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson’s disease. J Neurol 2002; 249 (07) 824-8.
- 24 Riley D, Lang AE, Blair RDG, Birnbaum A, Reid B. Frozen shoulder and other shoulder abnormalities in Parkinson´s disease. J Neurol Neurosurg Psych 1988; 52: 63-66.
- 25 Schmidt WJ, Schuster G, Wacker E, Pergande G. Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 1997; 327 (01) 1-9.
- 26 Schott GD. Pain in Parkinson’s disease. Pain 1985; 22 (04) 407-11.
- 27 Schwarz M, Nolden-Koch M, Purr J, Pergande G, Block F. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J Neural Transm Gen Sect 1996; 103 (05) 581-90.
- 28 Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976; 26 (05) 423-9.
- 29 Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29 (06) 312-21.
- 30 Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008; 14 (03) 205-212.
- 31 Starkstein SE, Preziosi TJ, Robinson RG. Sleep disorders, pain, and depression in Parkinson’s disease. Eur Neurol 1991; 31 (06) 352-5.
- 32 Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G. Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77 (07) 822-5.
- 33 Tiple D, Fabbrini G, Colosimo C, Ottaviani D, Camerota F, Defazio G, Berardelli A. Camptocormia in Parkinson disease: an epidemiological and clinical study. J Neurol Neurosurg Psychiatry 2009; 80 (02) 145-8.
- 34 Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, Barat M. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov Disord 1996; 11 (06) 729-32.
- 35 Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord 2001; 16 (02) 252-7.
- 36 von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2008; 23 (06) 889-92.